Wednesday, November 17, 2010
".....The team, testing 203 samples with OncoMap, found mutations of 50 genes in total. Some mutations were in genes previously identified in ovarian cancer, including KRAS, CTNNB1, and PIK3CA. Others were not previously known to occur in this disease, but, importantly, are potential drug targets with existing agents. "It’s not like HER2 in breast cancer where that is found in about 30% of breast cancers – we found many mutations in the ovarian cancer samples and they were infrequent," Dr. Matulonis said in a telephone interview prior to the conference; she noted, however, that OncoMap identified KRAS and PIK3CA mutations as the most common, occurring in about 25% of tumors, and "that was reassuring," as it was in line with expectations..........Dr. Matulonis’ team is now using OncoMap on all new ovarian cancers, including nonserous cancers, diagnosed at Dana-Farber, and she predicted the test will become standard in clinical practice within 6 months to a year..........cont'd
(Halifax, NS) Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer - MarketWatch
PARP (1 and 2) inhibitor, MK-4827, shows anti-tumor activity in first trial in humans (mutation/non mutation carriers)
"He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."
science article: Duke continues investigation as geneticist's work retracted (ovarian cancer patients to cisplatin drug therapy)
A prIME Oncology educational activity held after the official ESMO program hours: Evolving Strategies in the Management of Advanced Ovarian Cancer Oct
Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD
Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS
Beyond antiangiogenesis: What are the options?
Andres Poveda, MD
This Webcast contains video and downloadable slides from our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer,” a prIME Oncology educational activity that was held after the official ESMO program hours on Monday, 11 October in Milan, Italy.